Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of 131I-Omburtamab CED in DIPG
NCT05063357Phase 1Withdrawn
- Sponsor
- Y-mAbs Therapeutics, Inc.
- Start
- Mar 2022
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of 131I-omburtamab in diffuse intrinsic pontine glioma (DIPG), sponsored by Y-mAbs Therapeutics, Inc. Primary endpoint: Safety of 131I-omburtamab assessed by CTCAE v.5.0 at 2 years. Planned start Mar 2022; status: withdrawn.
02
Drugs
131I-omburtamab
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT05063357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063357.